Factors Affecting Hospitalization Length and in-Hospital Death Due to COVID-19 Infection in Saudi Arabia: A Single-Center Retrospective Analysis.
Al-Ahsa
COVID-19
Saudi Arabia
hospital stay
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
04
2023
accepted:
12
07
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
The emerging COVID-19 coronavirus disease has widely spread, causing a serious worldwide pandemic. Disease severity and mortality risk can be predicted using an analysis of COVID-19 clinical characteristics. Finding out what influences patients' hospitalization length and in-hospital mortality is crucial for decision-making and planning for emergencies. The goal of this study is to identify the factors that influence hospital stay length and in-hospital death due to COVID-19 infection. This cross-sectional study was conducted from August to October 2020 and included 630 patients with a confirmed diagnosis of COVID-19 infection. Using odds ratios (OR) and 95% confidence intervals (CI), a multivariable logistic regression model was used to assess the variables that are linked to longer hospital stays and in-hospital deaths. Most patients were male (64.3%), and most were older than 40 years (81.4%). The mean length of hospital stay (LoHS) was 10.4±11.6 days. The overall death rate among these COVID-19 cases was 14.3%. Non-survivors were older, had more comorbidities, had prolonged LoHS with increased ICU admission rates and mechanical ventilation usage, and had a more severe condition than survivors. ICU admission, low serum albumin, and elevated LDH levels were associated with longer LoHS, while ICU admission, DM, and respiratory diseases as comorbidities, total leukocytic count, and serum albumin were predictors of mortality. Longer LoHS due to COVID-19 infection was linked to ICU admission, low serum albumin, and elevated LDH levels, while the independent predictors of in-hospital death were ICU admission, DM, and respiratory diseases as comorbidities, total leukocytic count, and serum albumin.
Sections du résumé
Background
UNASSIGNED
The emerging COVID-19 coronavirus disease has widely spread, causing a serious worldwide pandemic. Disease severity and mortality risk can be predicted using an analysis of COVID-19 clinical characteristics. Finding out what influences patients' hospitalization length and in-hospital mortality is crucial for decision-making and planning for emergencies. The goal of this study is to identify the factors that influence hospital stay length and in-hospital death due to COVID-19 infection.
Methods
UNASSIGNED
This cross-sectional study was conducted from August to October 2020 and included 630 patients with a confirmed diagnosis of COVID-19 infection. Using odds ratios (OR) and 95% confidence intervals (CI), a multivariable logistic regression model was used to assess the variables that are linked to longer hospital stays and in-hospital deaths.
Results
UNASSIGNED
Most patients were male (64.3%), and most were older than 40 years (81.4%). The mean length of hospital stay (LoHS) was 10.4±11.6 days. The overall death rate among these COVID-19 cases was 14.3%. Non-survivors were older, had more comorbidities, had prolonged LoHS with increased ICU admission rates and mechanical ventilation usage, and had a more severe condition than survivors. ICU admission, low serum albumin, and elevated LDH levels were associated with longer LoHS, while ICU admission, DM, and respiratory diseases as comorbidities, total leukocytic count, and serum albumin were predictors of mortality.
Conclusion
UNASSIGNED
Longer LoHS due to COVID-19 infection was linked to ICU admission, low serum albumin, and elevated LDH levels, while the independent predictors of in-hospital death were ICU admission, DM, and respiratory diseases as comorbidities, total leukocytic count, and serum albumin.
Identifiants
pubmed: 37546239
doi: 10.2147/IJGM.S418243
pii: 418243
pmc: PMC10404051
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3267-3280Informations de copyright
© 2023 Al Omair et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
Lancet. 2020 Apr 18;395(10232):1305-1314
pubmed: 32247320
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Front Public Health. 2020 Nov 19;8:593256
pubmed: 33330336
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 May 14;382(20):1873-1875
pubmed: 32187459
J Infect Dev Ctries. 2020 Feb 29;14(2):125-128
pubmed: 32146445
J Gen Intern Med. 2020 May;35(5):1545-1549
pubmed: 32133578
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Medicina (Kaunas). 2021 Aug 26;57(9):
pubmed: 34577801
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211000231
pubmed: 33729040
BMC Infect Dis. 2021 Jun 14;21(1):574
pubmed: 34126954
JAMA Netw Open. 2020 Aug 03;3(8):e2018039
pubmed: 32809033
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Emerg Infect Dis. 2003 Sep;9(9):1064-9
pubmed: 14519241
J Multidiscip Healthc. 2021 Apr 15;14:839-852
pubmed: 33883900
Sci Rep. 2021 Mar 31;11(1):7310
pubmed: 33790365
Healthcare (Basel). 2023 Mar 03;11(5):
pubmed: 36900756
BMC Med. 2020 Sep 3;18(1):270
pubmed: 32878619
Pulmonology. 2020 Mar - Apr;26(2):114-115
pubmed: 32151613
Int J Med Sci. 2020 May 18;17(9):1281-1292
pubmed: 32547323
BMJ Open Diabetes Res Care. 2020 Apr;8(1):
pubmed: 32345579
Saudi Pharm J. 2021 Jul;29(7):682-691
pubmed: 34400862
J Epidemiol Glob Health. 2020 Mar;10(1):1-3
pubmed: 32175703
Pediatr Pulmonol. 2020 May;55(5):1169-1174
pubmed: 32134205
J Clin Med. 2020 Feb 20;9(2):
pubmed: 32093211
Diabetes Care. 2020 Aug 25;:
pubmed: 32843337
Healthcare (Basel). 2022 Jun 27;10(7):
pubmed: 35885728
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4585-4596
pubmed: 32373999
PLoS One. 2022 Jun 24;17(6):e0270062
pubmed: 35749537
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
PLoS One. 2021 Mar 18;16(3):e0248713
pubmed: 33735205
J Infect Dev Ctries. 2021 Jun 30;15(6):766-772
pubmed: 34242184
PLoS One. 2021 Sep 10;16(9):e0257131
pubmed: 34506551
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Signal Transduct Target Ther. 2021 Jul 7;6(1):255
pubmed: 34234112
Infect Dis Poverty. 2020 Mar 17;9(1):29
pubmed: 32183901
Medicine (Baltimore). 2020 Jun 19;99(25):e20660
pubmed: 32569196
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
PLoS One. 2021 Apr 29;16(4):e0250955
pubmed: 33914805
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Infect Drug Resist. 2021 Oct 05;14:4097-4105
pubmed: 34675555
J Multidiscip Healthc. 2021 Aug 12;14:2169-2183
pubmed: 34408431
J Infect Public Health. 2020 Dec;13(12):1833-1839
pubmed: 32788073
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Epidemiol Glob Health. 2020 Sep;10(3):214-221
pubmed: 32954712
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Infect. 2020 Jun;80(6):e14-e18
pubmed: 32171866
PLoS One. 2022 Jan 14;17(1):e0261216
pubmed: 35030181
J Biol Regul Homeost Agents. 2020 Apr 07;34(2):339-343
pubmed: 32253888
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
Aging (Albany NY). 2020 Aug 28;12(16):15938-15945
pubmed: 32855361
Front Med (Lausanne). 2022 Jul 13;9:893954
pubmed: 35911421
Saudi Pharm J. 2021 Oct;29(10):1096-1101
pubmed: 34366685
Clin Chem Lab Med. 2020 Jun 25;58(7):1095-1099
pubmed: 32301746
Aging (Albany NY). 2020 Jun 24;12(12):11245-11258
pubmed: 32633729